Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 22, 2004. The report details corporate actions regarding share repurchases and updates on directors' interests in company shares and employee benefit plans.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on specific transactional data:
- Share Repurchase (March 18): 930,000 ordinary shares purchased for cancellation at 1066.58p per share.
- Share Repurchase (March 19): 1,850,000 ordinary shares purchased for cancellation at 1064.80p per share.
- US Retirement Savings Plan: Ordinary Share ADRs held by the fund decreased from 18,925,448 to 18,865,547 at an average price of $39.63.
- Employee Trust Transfer: 2,991 Ordinary Shares transferred from the GSK Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Material Changes
The filing reports a reduction in the company's outstanding share count due to the cancellation of 2,780,000 shares purchased on March 18 and March 19, 2004. Additionally, there was a minor decrease in the number of ADRs held by the US Retirement Savings Plan and a transfer of shares from the Employee Trust to plan participants.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transactions were executed in accordance with authority granted by shareholders at the Annual General Meeting on May 19, 2003.
Key Facts for Investor Verification
- Total of 2,780,000 shares were repurchased and cancelled in mid-March 2004.
- Repurchase prices ranged between 1064.80p and 1066.58p per share.
- Directors Dr J P Garnier, Dr T Yamada, and Mr J D Coombe have potential interests in shares held within the US Retirement Savings Plan and the GSK Employee Trust.
- The filing does not contain quarterly or annual financial performance data.